Ernexa Therapeutics Inc
ERNA
NASDAQ
Biotechnology
$4.27
USD
-0.03 (-0.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.22M
Volume 21.5K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-12.26M
TTM
+72.0%
YoY
Operating Cash Flow
$-8.84M
TTM
+38.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | -100.0% | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.4 | 1.0 | 1.4 | 1.6 | 1.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 |
Total Operating Expenses | 2.5 | 2.0 | 2.1 | 5.6 | 4.1 |
Operating Income | -2.5 | -2.0 | -2.1 | -5.6 | -4.1 |
EBITDA | -2.5 | -2.0 | -1.9 | -3.5 | -4.1 |
Other Income / Expense | -0.6 | 0.7 | 0.5 | 0.0 | 0.0 |
Total Other Income / Expense | -0.6 | 0.8 | 0.5 | 0.0 | 0.1 |
Income Before Income Taxes | -3.1 | -1.2 | -1.6 | -5.5 | -4.0 |
Income Taxes | 0.0 | 0.0 | -0.1 | -0.0 | 0.0 |
Net Income | -3.1 | -1.2 | -1.5 | -5.5 | -4.0 |
Consolidated Net Income / Loss | -3.1 | -1.2 | -1.5 | -5.5 | -4.0 |
Net Income Attributable to Common Shareholders | -3.1 | -1.2 | -1.5 | -5.5 | -4.0 |
Basic EPS | -$15.19 | -$3.75 | -$4.56 | -$6.95 | -$3.40 |
Diluted EPS | -$15.19 | -$3.75 | -$4.56 | -$6.95 | -$3.40 |
Basic Shares Outstanding | 0.2M | 0.3M | 0.3M | 0.8M | 1.2M |
Diluted Shares Outstanding | 0.2M | 0.3M | 0.3M | 0.8M | 1.2M |